Skip to content

Intergrated Differentiation between Glioma Recurrence and Pseudoprogression: the Molecular Pathology, Radiomics and Immunological Characteristics

Intergrated Differentiation of Glioma Recurrence from Treatment-induced Changes: the Molecular Pathology, Radiomics and Immunological Characteristics

Status
Recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000033985
Enrollment
Unknown
Registered
2020-06-20
Start date
2020-06-20
Completion date
Unknown
Last updated
2020-06-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Glioma

Interventions

Gold Standard:Pathological examination after reoperation.
Index test:A&#32
diagnosis&#32
model&#32
and&#32
pseudoprogression&#32
of&#32
after&#32

Sponsors

Zhongnan Hospital of Wuhan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. The informed consent of the trial has been signed with the patient before the trial; 2. Patients over 18 years old; 3. Patients with glioma confirmed by pathology; 4. Patients who have undergone total or subtotal resection of tumor and received radiotherapy and / or chemotherapy; 5. Patients with expected survival >= 6 months.

Exclusion criteria

Exclusion criteria: 1. Patients without surgery; 2. Patients who cannot tolerate complete MRI examination.

Design outcomes

Primary

MeasureTime frame
Pathological diagnosis;Molecular pathologic diagnosis;Brain MRI;Levels of immune cells and immune factors in blood;Levels of immune cells and immune factors in CSF;Levels of immune cells and immune factors in feces;SEN, SPE, ACC, AUC of ROC;

Countries

China

Contacts

Public ContactZhiqiang Li

Zhongnan Hospital of Wuhan University

lifenzhi@163.com+86 18907123005

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026